BioSpace News Archive

Moderna Inc. today announced that it has submitted for authorization with Health Canada for the evaluation of a 50 µg two-dose series of SPIKEVAX™ (elasomeran mRNA vaccine) 1 in children ages 6 to 11 years.

Nanox Announces Third Quarter 2021 Financial Results and Provides Business Update.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors.

Agenus Inc. today announced that Dr. Garo Armen, Chairman and Chief Executive Officer of Agenus and Dr. Steven O’Day, Chief Medical Officer, will participate in a fireside chat hosted by Evercore on Tuesday, November 30th, 2021 at 1:50 PM EST.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that, effective immediately, Louise Rodino-Klapac, Ph.D., executive vice president and chief scientific officer, has been named the Company’s head of research and development (R&D) and will continue to serve in the role of chief scientific officer.

As per a recent report by Transparency Market Research pertaining to global breast cancer therapeutics market states that the market is projected to grow substantially in from 2016 to 2024.

According to the report, the global in-vitro transcription templates market was valued at ~US$ 120 Mn in 2020 and is projected to expand at a CAGR of ~20% from 2021 to 2030.

Transparency Market Research has published a new report titled ‘Medical Devices Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global medical devices contract manufacturing market was valued at US$ 47.5 Bn in 2017.

Pen needles are used in combination with pen injectors for the delivery of injectable medications. A pen needle comprises a hollow needle which is fixed in a plastic hub and connects to the injection pen.

OSE Immunotherapeutics SA and the FoRT Foundation announced that the first patient has been randomized in the Phase 2 clinical trial evaluating Tedopi® in combination with Opdivo® or chemotherapy as second-line treatment in patients with metastatic non-small cell lung cancer.